KZIA Stock Analysis: Buy, Sell, or Hold?
KZIA - Kazia Therapeutics Limited American Depositary Shares
$14.69
0.69 (4.93%)
▲
5d:
+4.33%
30d:
+11.54%
90d:
+106.32%
BUY
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Feb 06, 2026
0d
Get Alerted When KZIA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: KZIA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: KZIA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: KZIA is currently trading at $14.69, which is considered extended relative to its 30-day fair value range of $11.62 to $13.82.
Technical Outlook: Technically, KZIA is in a strong uptrend. The price is approaching resistance at $13.31. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.9% recently.
Market Sentiment: KZIA has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $25.74 (+75.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, KZIA is in a strong uptrend. The price is approaching resistance at $13.31. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.9% recently.
Market Sentiment: KZIA has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $25.74 (+75.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$11.62 -
$13.82
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range (+6.3% above its trading range)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.9%)
- BULLISH: Trading 75.2% below Wall St target ($25.74)
Trading Range Analysis
30-Day Trading Range
$11.62 -
$13.82
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$10.59
Resistance Level
$13.32
Current Trend
Strong Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-670.78
Wall Street Target
$25.74
(+75.2%)
Revenue Growth (YoY)
312.4%
Share & Embed Analysis
Last updated: June 24, 2026 6:25 AM ET
Data refreshes hourly during market hours. Next update: 7:25 AM
Data refreshes hourly during market hours. Next update: 7:25 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KZIA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 67 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 67 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 65 BUY |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$257 | 59 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
BUY
20 analysts |
$32 | 65 BUY |
